Slide 1: Third Quarter & Nine Months Ended September 2024 Investors Call
November 2024 Third Quarter & Nine Months Ended September 2024 Investors Call
Slide 2: Forward-Looking Statement
FORWARD - LOOKING STATEMENT This presentation is not intended to provide investment or medical advice . It should be noted that some products under development described herein have not been found safe or effective by any regulatory agency and are not approved for any use outside of clinical trials
Slide 3: Kamada - A Global Biopharmaceutical Company
KEDRAB® CYTOGAM® HEPGAM B® VARIZIG® WINRHO® GLASSIA® KAMADA - A GLOBAL BIOPHARMACEUTICAL COMPANY 6 FDA - Approved Products 15 % CAGR (from 2021 ) $ 158 - 162 M 2024 Revenues Guidance $ 32 - 35M 1 2024 Adj. EBIDTA Guidance 4 Pillars of Growth A LEADER IN SPECIALTY PLASMA THERAPIES, WITH A PORTFOLIO O
Slide 4: Delivering on Our Commitments
DELIVERING ON OUR COMMITMENTS 4
Slide 5: Q3 - Continuing the Growth: Double Digit Revenue and Profitable Increase
Q 3 – 24 CONTINUING THE GROWTH DOUBLE DIGIT REVENUE AND PROFITABLE INCREASE 5 For reconciliation of Adjusted EBITDA please refer to slide 16 GROSS MARGIN REVENUE 2% Q3/23 39% Q 3 / 24 41 % 10% Q3/23 $37.9 Q 3 / 24 $ 41.7 Adj. EBITDA EPS 11% Q3/23 $7.9 Q 3 / 24 $ 8.8 16% Q3/23 $0.06 Q3/24 $0.07
Slide 6: 9M-24 Continuing the Growth: Double Digit Revenue and Profitable Increase
GROSS MARGIN REVENUE 4% 9M/23 39% 9 M/ 24 43 % 15 % 9M/23 $106.1 9 M/ 24 $ 121.9 Adj. EBITDA EPS 43% 9M/23 $17.7 9 M/ 24 $ 25.4 X3 9M/23 $0.06 9M/24 $0.18 9 M – 24 CONTINUING THE GROWTH DOUBLE DIGIT REVENUE AND PROFITABLE INCREASE 6 For reconciliation of Adjusted EBITDA please refer to slide 16
Slide 7: Annual Double-Digit Growth Trajectory
6 18 24 32 - 35 1 2021 2022 2023 2024 104 129 143 158 – 162 2021 2022 2023 2024 ADJUSTED EBITDA US$M 77% CAGR 2024 represents annual guidance 2024 represents annual guidance ANNUAL DOUBLE - DIGIT GROWTH TRAJECTORY REVENUES US$M 15% CAGR 9 M $ 122 M ( 76 %) 7 9 M $ 25 M ( 76 %) 1. Adjusted EBITDA gui
Slide 8: Kamada's Roadmap for Annual Double-Digit Growth
KAMADA ’ S ROADMAP FOR ANNUAL DOUBLE - DIGIT GROWTH 8 Organic Growth Portfolio of 6 FDA - approved products; Over 30 territories M&A Transactions Support growth through M&A transactions Plasma Collection Centers Each new collection center contributes annual revenues of $ 8 M - $ 10 M Inhaled AAT Pha
Slide 9: FDA-Approved Specialty Plasma Products
9 6 FDA - APPROVED SPECIALTY PLASMA PRODUCTS KEDRAB® [Rabies Immune Globulin (Human)] Post exposure prophylaxis of rabies infection CYTOGAM® [Cytomegalovirus Immune Globulin (Human)] Prophylaxis of CMV disease associated with transplants HEPGAM B® [Hepatitis B Immune Globulin (Human)] Prevention of
Slide 10: Distribution Segment Growth
DISTRIBUTION SEGMENT GROWTH More than 25 products exclusively licensed from leading international pharmaceutical companies, marketed in the Israeli market EXCLUSIVE DISTRIBUTOR IN ISRAEL FOR LEADING BIOPHARMACEUTICAL COMPANIES Key areas : plasma - derived, respiratory, rare diseases, infectious dise
Slide 11: M&A Transactions: Seeking the Next Breakthrough
11 M&A TRANSACTIONS SEEKING THE NEXT BREAKTHROUGH Exploring strategic business development opportunities to identify potential acquisition or in - licensing Focusing on products synergistic to our existing commercial and/or production activities Strong financial position and proven successful M&A ca
Slide 12: Kamada Plasma: Expanding Vertical Integration & Revenue Growth
12 KAMADA PLASMA EXPANDING VERTICAL INTEGRATION & REVENUE GROWTH Collecting hyper - immune plasma for our specialty IgG products and normal source plasma (NSP) to support revenue growth Recently opened a new plasma collection center in Houston, Texas ; planning to open another center in San Antonio,
Slide 13: Inhaled AAT Phase 3 Pivotal Study
INHALED AAT PHASE 3 PIVOTAL STUDY Non - Invasive, at - home treatment. Expected better ease of use and quality of life for AATD patients than current IV SOC Most effective mode of treatment for delivering therapeutic amounts of AAT directly into the airways Studied in more than 200 individuals to da
Slide 14: Inhaled AAT Phase 3 Pivotal Study: Market Opportunity and FDA Discussions
$ 2 Billion A substantial market opportunity ( 2028 ) In discussion with the FDA on an IND amendment with revised statistical analysis plan and study protocol FDA recently reconfirmed overall study design, endorsed positive safety data to date, and expressed willingness to potentially accept a P< 0.
Slide 15: Financial Details
15 DETAILS FY 2023 Q3/23 Q3/24 9M/23 9M/24 US $ M Driven by two key growth drivers, KEDRAB® & CYTOGAM® 115.5 31.4 37.1 86.4 110.0 PROPRIETARY 27.1 6.5 4.6 19.7 11.9 DISTRIBUTION 15% YoY increase; 9M revenues - 76% of mid - point annual guidance 142.5 37.9 41.7 106.1 121.9 TOTAL REVENUES 55.5 14.8 17
Slide 16: Non-IFRS Measures - Adjusted EBITDA
16 NON - IFRS MEASURES – ADJUSTED EBITDA FY 2023 Q 3 / 23 Q 3 / 24 9 M/ 23 9 M/ 24 US $ M 8.3 3.2 3.9 3.2 10.7 NET PROFIT 0.1 0.1 0.1 0.2 0.2 TAXES ON INCOME 1.0 1.3 1.8 3.4 5.3 REVALUATION OF ACQUISITION RELATED CONTINGENT CONSIDERATION 0.7 ( 0.2 ) ( 0.4 ) 0.5 ( 1.2 ) OTHER FINANCIAL EXPENSE, NET 7
Slide 17: Kamada - Significant Upside Potential
KEDRAB® CYTOGAM® HEPGAM B® VARIZIG® WINRHO® GLASSIA® KAMADA - SIGNIFICANT UPSIDE POTENTIAL 6 FDA - Approved Products 15 % CAGR (from 2021 ) $ 158 - 162 M 2024 Revenues Guidance $ 32 - 35M 1 2024 Adj. EBIDTA Guidance 4 Pillars of Growth DELIVERING ON OUR COMMITMENTS $ 72.0 M Cash (Sep 30, 2024) 17 Or
Slide 18: Thank You
THANK YOU www.kamada.com